Allarity Therapeutics Inc ALLR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.05
- Day Range
- $1.01–1.08
- 52-Week Range
- $0.77–1.84
- Bid/Ask
- $1.05 / $1.07
- Shares Outstanding
- 15.91M
- Market Cap
- $16.55M
- Volume/Avg
- 74,353 / 103,431
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 48.15
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.allarity.com
Valuation
|
Metric
|
ALLR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.77 |
Price/Sales | 48.15 |
Price/Cash Flow | — |
Price/Earnings
ALLR
Financial Strength
|
Metric
|
ALLR
|
|---|---|
Quick Ratio | 0.64 |
Current Ratio | 1.11 |
Interest Coverage | −11.27 |
Quick Ratio
ALLR
Profitability
|
Metric
|
ALLR
|
|---|---|
Return on Assets (Normalized) | −40.96% |
Return on Equity (Normalized) | −117.27% |
Return on Invested Capital (Normalized) | −54.57% |
Return on Assets
ALLR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|FtZt?Qd | LOCK|X$&Z | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|V>lpG& | LOCK|Dv#^ | $76B | |||
| Moderna Inc
MRNA
| LOCK|t#GF^>< | LOCK|Pf | $75B | |||
| argenx SE ADR
ARGX
| LOCK|vhv^q# | LOCK|<p | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&pSm$^< | LOCK|#V | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?tw!$Zq | LOCK|x%wQ> | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>k&JVV> | LOCK|&DK@q | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|@HtxLl | LOCK|hQ | $24B | |||
| Incyte Corp
INCY
| LOCK|Y@Q#>> | LOCK|fl | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^B!#?Hp | LOCK|<> | $15B |
United States